Format

Send to

Choose Destination
Environ Res. 2018 Jan;160:314-321. doi: 10.1016/j.envres.2017.10.014. Epub 2017 Oct 15.

Perfluoroalkyl substances, bone density, and cardio-metabolic risk factors in obese 8-12 year old children: A pilot study.

Author information

1
Department of Population and Public Health Sciences, Boonshoft School of Medicine, Wright State University, 3123 Research Blvd, Suite #200, Dayton, OH 45420, USA. Electronic address: naila.khalil@wright.edu.
2
The Pediatric Lipid Clinic, Dayton's Children Hospital, One Children's Plaza, Dayton, OH 45404, USA. Electronic address: james.ebert@wright.edu.
3
Wadsworth Center, New York State Department of Health, Albany, NY 12201-0509, USA. Electronic address: Masato.Honda@health.ny.gov.
4
Department of Epidemiology, Human Genetics & Environmental Sciences, The Universit y of Texas Health Science Center School of Public Health, One West University Blvd, SPH Building N1.102B, Brownsville, TX 78520, USA. Electronic address: miryoung.lee@uth.tmc.edu.
5
Department of Population and Public Health Sciences, and Department of Psychiatry, Boonshoft School of Medicine, Wright State University, 3123, Research Blvd, Suite #200, Dayton, OH 45420, USA. Electronic address: ramzi.nahhas@wright.edu.
6
Cancer Research and Translational Medicine Research Unit and MRC Oulu, Faculty of Medicine, University of Oulu, P.O.Box 5000, FIN-90014 Oulu, Finland. Electronic address: antti.koskela@oulu.fi.
7
Wright State University, Dayton, OH, 45435, USA. Electronic address: thomas.hangartner@wright.edu.
8
Wadsworth Center, New York State Department of Health and Department of Environmental Health Sciences, State University of New York, Albany, NY 12201-0509, USA. Electronic address: kurunthachalam.kannan@health.ny.gov.

Abstract

BACKGROUND AND OBJECTIVE:

Perfluoroalkyl substances (PFASs), including perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), perfluorohexane sulfonic acid (PFHxS), and perfluorononanoic acid (PFNA), have been associated with adverse bone, and metabolic changes in adults. However association of PFASs with bone health in children is understudied. Considering their role as endocrine disruptors, we examined relationships of four PFASs with bone health in children.

METHODS:

In a cross sectional pilot study, 48 obese children aged 8-12 years were enrolled from Dayton's Children Hospital, Ohio. Anthropometric, clinical and biochemical assessments of serum were completed. Serum PFASs were measured by UPLC-ESI-MS/MS. In a subset of 23 children, bone health parameters were measured using calcaneal quantitative ultrasound (QUS).

RESULTS:

While PFASs exposure was associated with a consistent negative relationship with bone health parameters, among four PFASs tested, only PFNA showed a significant negative relationship with bone parameter (β [95% CI], = - 72.7 [- 126.0, - 19.6], p = .010). PFNA was also associated with raised systolic blood pressure (p = .008), low density lipoprotein cholesterol (LDL-C; p < .001), and total cholesterol (TC; p = .014). In addition, both PFOA and PFOS predicted elevation in LDL-C, and PFOA predicted increased TC, as well. In this analysis, PFASs were not strongly related to thyroid hormones, 25-hydroxy vitamin D, liver enzymes, or glucose homeostasis.

CONCLUSION:

PFASs exposure in obese children may play a role in adverse skeletal and cardiovascular risk profiles.

KEYWORDS:

Bone; Children; Metabolic; Perfluoroalkyl substances (PFASs); Perfluorononanoic acid (PFNA)

PMID:
29040951
DOI:
10.1016/j.envres.2017.10.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center